Loading
A phase 1 trial of PAS-004 run by Pasithea Therapeutics Corp., now recruiting.
PAS-004 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06299839 by Pasithea Therapeutics Corp., with 83 participants planned, started 2024-02-29. Conditions recorded: RAS Mutation, NF1 Mutation, RAF Mutation and Advanced Solid Tumors. Interventions recorded: PAS-004 Capsules and PAS-004 Tablets.
Shares PAS-004, Pasithea Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/